Osteoporosis

Condition: Osteoporosis  |  Category: Bone and Metabolic Health  |  Reviewed by: Brian Lamkin, DO

What Is Osteoporosis?

Osteoporosis is a skeletal disorder characterized by reduced bone mineral density and impaired bone microarchitecture producing increased fracture risk. It arises from an imbalance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation, with resorption chronically exceeding formation. This imbalance has modifiable drivers including hormonal decline, nutritional deficiency, chronic inflammation, mechanical underloading, and gut malabsorption that are almost never comprehensively evaluated before pharmaceutical intervention is initiated.

The standard diagnostic approach uses DEXA scan T-scores: osteoporosis is defined as a T-score of -2.5 or lower; osteopenia is -1.0 to -2.5. While DEXA provides bone density information, it cannot characterize the dynamic rate of bone remodeling, the hormonal and nutritional drivers of bone loss, or the relative contribution of resorption versus formation to the deficit. Bone turnover markers that provide this information are almost never measured before deciding on treatment.

Why It Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

Bone remodeling is a continuous process of coordinated resorption and formation that maintains skeletal integrity throughout life. RANK-L from osteoblasts and T-cells signals osteoclasts to resorb bone; osteoprotegerin (OPG) inhibits this signal. Estrogen and testosterone directly inhibit RANK-L expression and promote OPG production; their decline removes the primary brake on osteoclast activity. Cortisol excess directly suppresses osteoblast function and activates osteoclasts; HPA axis dysfunction is among the most under-recognized drivers of bone loss.

Nutritional drivers are multiple and concurrent. Calcium is necessary but not sufficient. Vitamin D is required for calcium absorption and has direct receptors on osteoblasts. Vitamin K2 activates osteocalcin, the protein that binds calcium into the bone matrix; without K2 activation, absorbed calcium is not effectively incorporated into bone and may deposit in arteries instead. Magnesium is required for vitamin D metabolism and is a structural component of the bone mineral matrix. Silica supports collagen cross-linking in the organic bone matrix. All of these are modifiable and rarely assessed together.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

A complete osteoporosis evaluation requires dynamic bone remodeling markers alongside the hormonal and nutritional characterization that determines the primary drivers of bone loss.

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The perimenopausal woman missing the critical bone loss window: DEXA not recommended until age 65 by standard guidelines; presenting at age 52 with T-score of -2.1 and documented height loss of 1 inch; the most rapid bone loss occurred between ages 48 and 52 during the perimenopausal estrogen transition without any evaluation or intervention; immediate hormonal and nutritional intervention with progressive resistance training begins rebuilding bone density
• The patient on bisphosphonate therapy continuing to lose bone: alendronate for 5 years; repeat DEXA shows continued bone loss; bone turnover markers reveal elevated P1NP indicating the primary problem is inadequate formation, not excess resorption; bisphosphonate suppresses resorption but cannot address formation failure; PTH analogue therapy and anabolic support produce the improvement bisphosphonate alone could not
• The man with undiagnosed osteoporosis from testosterone deficiency: T-score of -2.8 discovered incidentally; testosterone of 220 ng/mL with free testosterone in the bottom 10% of range; testosterone replacement produces measurable bone density improvement within 12 months alongside vitamin D and K2 optimization; the hormonal driver that could have been identified and treated years earlier
• The patient whose bone density improves dramatically with vitamin K2 and vitamin D: T-score of -1.8 at baseline; declines bisphosphonate; vitamin D optimized to 72 ng/mL, vitamin K2 200 mcg MK-7 initiated, magnesium added, resistance training started; repeat DEXA at 2 years shows T-score improvement to -1.2; the nutritional intervention produced results standard of care said were not achievable without medication

Treatment and Optimization Strategy

What Most Doctors Miss

• Bone turnover markers are not measured before choosing treatment: CTX-beta measures the rate of bone resorption; P1NP measures the rate of bone formation; the ratio characterizes whether the primary problem is excess resorption, insufficient formation, or both; bisphosphonate therapy is appropriate for high-resorption patterns but not for low-formation patterns where anabolic support is required; without these markers, treatment selection is based solely on T-score
• Vitamin K2 is not included in standard osteoporosis protocols: osteocalcin requires vitamin K2 for carboxylation to function; uncarboxylated osteocalcin cannot bind calcium into bone; vitamin K2 MK-7 also activates matrix Gla protein that prevents calcium from depositing in arteries; this is the mechanism by which calcium supplementation without K2 may increase vascular calcification risk; K2 is the missing nutrient in the standard calcium-D protocol
• Cortisol excess from HPA axis dysfunction as a bone loss driver is not evaluated: glucocorticoids directly suppress osteoblast differentiation, activate osteoclasts through RANK-L upregulation, reduce calcium absorption, and suppress sex hormone production that further impairs bone formation; HPA axis dysregulation producing cortisol excess is an under-recognized and correctable driver of bone loss
• The perimenopausal window of maximal bone loss is not managed: standard guidelines delay bone density screening until 65; by this time the 3-5 years of most rapid bone loss following estrogen withdrawal have occurred without evaluation or intervention; initiating hormonal and nutritional support during the perimenopausal transition prevents the loss that later requires pharmaceutical treatment

When to Seek Medical Care

Seek evaluation for osteoporosis risk if you are a postmenopausal woman, a man over 50 with risk factors including testosterone deficiency or chronic glucocorticoid use, or any person with a family history of hip fracture, chronic inflammatory conditions, malabsorption syndromes, or prolonged steroid use. Do not wait for a fracture to establish bone density baseline and identify modifiable drivers.

Seek prompt evaluation if you sustain a low-energy fracture at any age, experience significant height loss, develop new back pain from possible vertebral compression, or are initiating or discontinuing hormonal therapy and need bone density monitoring.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Osteoporosis

At The Lamkin Clinic, osteoporosis evaluation begins with bone turnover markers alongside the standard DEXA, plus a complete hormonal panel including estradiol, testosterone, DHEA-S, and cortisol, inflammatory markers, and nutritional assessment including vitamin D, K2 status, and RBC magnesium. We identify the dominant driver of bone loss and match the treatment accordingly. Hormone therapy is offered to appropriate candidates as the most potent bone-protective intervention. Resistance training is specifically prescribed with progressive loading parameters.

Related Conditions

Related Symptoms